AstraZeneca announces $50bn US investment in manufacturing and R&D

AstraZeneca PLC (LSE:AZN) has unveiled plans to invest $50 billion in the United States by 2030, marking its largest-ever commitment to a single country and signalling a major boost for domestic drug manufacturing and research. The centrepiece of the investment is a proposed multi-billion-dollar drug manufacturing facility in Virginia, which would be the company's largest single site worldwide.